JP2020094063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020094063A5 JP2020094063A5 JP2020046007A JP2020046007A JP2020094063A5 JP 2020094063 A5 JP2020094063 A5 JP 2020094063A5 JP 2020046007 A JP2020046007 A JP 2020046007A JP 2020046007 A JP2020046007 A JP 2020046007A JP 2020094063 A5 JP2020094063 A5 JP 2020094063A5
- Authority
- JP
- Japan
- Prior art keywords
- irna agent
- uridine
- nucleotides
- sequence
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 29
- 125000003729 nucleotide group Chemical group 0.000 claims 21
- 239000002773 nucleotide Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000000692 anti-sense effect Effects 0.000 claims 5
- 108091081021 Sense strand Proteins 0.000 claims 4
- 229940045145 uridine Drugs 0.000 claims 3
- 102100037242 Amiloride-sensitive sodium channel subunit alpha Human genes 0.000 claims 2
- 101710194189 Amiloride-sensitive sodium channel subunit alpha Proteins 0.000 claims 2
- -1 Aminopropyl Chemical group 0.000 claims 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014418 Electrolyte imbalance Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000026709 Liddle syndrome Diseases 0.000 claims 1
- 208000037273 Pathologic Processes Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000009054 pathological process Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162309A JP2022188234A (ja) | 2007-06-15 | 2022-10-07 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07110376 | 2007-06-15 | ||
| EP07110376.6 | 2007-06-15 | ||
| EP07114265 | 2007-08-13 | ||
| EP07114265.7 | 2007-08-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017149211A Division JP6680728B2 (ja) | 2007-06-15 | 2017-08-01 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162309A Division JP2022188234A (ja) | 2007-06-15 | 2022-10-07 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020094063A JP2020094063A (ja) | 2020-06-18 |
| JP2020094063A5 true JP2020094063A5 (enExample) | 2020-08-06 |
| JP7157775B2 JP7157775B2 (ja) | 2022-10-20 |
Family
ID=40130244
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511658A Expired - Fee Related JP5485146B2 (ja) | 2007-06-15 | 2008-06-13 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2014029519A Expired - Fee Related JP5719047B2 (ja) | 2007-06-15 | 2014-02-19 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2015055783A Expired - Fee Related JP6193906B2 (ja) | 2007-06-15 | 2015-03-19 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2017149211A Expired - Fee Related JP6680728B2 (ja) | 2007-06-15 | 2017-08-01 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2020046007A Active JP7157775B2 (ja) | 2007-06-15 | 2020-03-17 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2022162309A Pending JP2022188234A (ja) | 2007-06-15 | 2022-10-07 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511658A Expired - Fee Related JP5485146B2 (ja) | 2007-06-15 | 2008-06-13 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2014029519A Expired - Fee Related JP5719047B2 (ja) | 2007-06-15 | 2014-02-19 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2015055783A Expired - Fee Related JP6193906B2 (ja) | 2007-06-15 | 2015-03-19 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2017149211A Expired - Fee Related JP6680728B2 (ja) | 2007-06-15 | 2017-08-01 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162309A Pending JP2022188234A (ja) | 2007-06-15 | 2022-10-07 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
Country Status (26)
| Country | Link |
|---|---|
| US (12) | US7718632B2 (enExample) |
| EP (7) | EP2171059A2 (enExample) |
| JP (6) | JP5485146B2 (enExample) |
| KR (2) | KR101653008B1 (enExample) |
| CN (1) | CN101778941B (enExample) |
| AR (1) | AR066984A1 (enExample) |
| AU (1) | AU2008263876B2 (enExample) |
| BR (1) | BRPI0813680A8 (enExample) |
| CA (1) | CA2690674C (enExample) |
| CL (1) | CL2008001756A1 (enExample) |
| CO (1) | CO6251331A2 (enExample) |
| CR (1) | CR11136A (enExample) |
| CU (1) | CU23774A3 (enExample) |
| EA (1) | EA200901653A1 (enExample) |
| EC (1) | ECSP099794A (enExample) |
| ES (6) | ES2432643T3 (enExample) |
| GT (1) | GT200900315A (enExample) |
| IL (1) | IL202366A0 (enExample) |
| MA (1) | MA31564B1 (enExample) |
| MX (1) | MX2009013609A (enExample) |
| PE (1) | PE20090942A1 (enExample) |
| SG (3) | SG169988A1 (enExample) |
| SV (1) | SV2009003434A (enExample) |
| TN (1) | TN2009000521A1 (enExample) |
| TW (3) | TWI444474B (enExample) |
| WO (1) | WO2008152131A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60326961D1 (de) * | 2002-07-26 | 2009-05-14 | Novartis Vaccines & Diagnostic | Modifizierte kleine irns moleküle und methoden zu deren anwendung |
| KR100473148B1 (ko) * | 2002-11-27 | 2005-03-10 | (주)텔리언 | 버스트모드 패킷 전달을 위한 정합장치 및 방법 |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| CA2581651C (en) * | 2004-10-01 | 2014-12-16 | Novartis Vaccines And Diagnostics, Inc. | Cholesterol-labelled modified rna |
| AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| BRPI0920933A2 (pt) * | 2008-11-26 | 2019-09-24 | Merck Sharp & Dohme | molécula de ácido nucleico de dupla fita, composição farmacêutica, e, método para tratar um indivíduo humano sofrendo de uma condição |
| EP2756845B1 (en) * | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
| WO2010111891A1 (zh) * | 2009-04-03 | 2010-10-07 | 北京大学 | 修饰的寡聚核酸分子及其制备方法和应用 |
| CN103275978B (zh) * | 2009-04-03 | 2014-10-29 | 百奥迈科生物技术有限公司 | 修饰的小干扰核酸及其制备方法 |
| US20120207818A1 (en) * | 2009-07-14 | 2012-08-16 | Shinohara Fumikazu | Composition for suppressing expression of target gene |
| CA2780741C (en) * | 2009-10-12 | 2023-04-04 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| AU2010332881B2 (en) | 2009-12-18 | 2015-01-22 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat HSF1-related diseases |
| AU2011244335B2 (en) | 2010-04-23 | 2015-06-04 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat Beta-ENaC-related diseases |
| US8916352B2 (en) * | 2011-04-08 | 2014-12-23 | Bio-Rad Laboratories, Inc. | PCR reaction mixtures with decreased non-specific activity |
| JP2014519806A (ja) | 2011-04-20 | 2014-08-21 | スミス ホールディングス，エルエルシー | 細胞内で自己会合し、ＲＮＡｉ活性を産生する組成物を使用した遺伝子発現を調節するための方法および成分 |
| MX344807B (es) * | 2011-06-21 | 2017-01-09 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3). |
| EP2751272A2 (en) | 2011-09-02 | 2014-07-09 | Novartis AG | Organic compositions to treat hsf1-related diseases |
| EP3535397B1 (en) | 2016-11-01 | 2022-01-05 | Arrowhead Pharmaceuticals, Inc. | Alpha-v beta-6 integrin ligands and uses thereof |
| US10590416B2 (en) * | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
| MX2020003554A (es) * | 2017-10-31 | 2020-08-03 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de enac. |
| US11597701B2 (en) * | 2017-11-01 | 2023-03-07 | Arrowhead Pharmaceuticals, Inc. | Integrin ligands and uses thereof |
| CN109364248B (zh) * | 2018-10-16 | 2021-05-18 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
| WO2021041776A1 (en) * | 2019-08-30 | 2021-03-04 | United States Government As Represented By The Department Of Veterans Affairs | Liposomal troponoid compound formulations |
| US12415840B2 (en) | 2020-02-21 | 2025-09-16 | Brookhaven Science Associates, Llc | Modified form of oleosin that when expressed in plants leads to increased triacylglycerol (oil) accumulation |
| WO2022216920A1 (en) | 2021-04-08 | 2022-10-13 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
| US11957178B2 (en) | 2021-11-15 | 2024-04-16 | Apackaging Group Llc | Aerosol actuator |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4534899A (en) * | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4426330A (en) * | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4837026A (en) * | 1985-10-03 | 1989-06-06 | Rajakhyaksha Vithal J | Transdermal and systemic preparation and method |
| DE3604625C2 (de) * | 1986-02-14 | 1994-01-20 | Bmw Rolls Royce Gmbh | Gasturbine |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US5451670A (en) * | 1987-12-09 | 1995-09-19 | City Of Hope | Restriction fragment length polymorphism test for haplotyping domesticated fowl |
| GB8824593D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
| US5013566A (en) * | 1988-12-19 | 1991-05-07 | Sampson Michael James | Process for obtaining improved yields from plants used for hay making by using a coating agent |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5665710A (en) * | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
| JP3220180B2 (ja) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| JP3351476B2 (ja) * | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| RU2143903C1 (ru) * | 1993-02-19 | 2000-01-10 | Ниппон Синяку Ко., Лтд. | Фармацевтическая композиция, содержащая сополимер нуклеиновой кислоты |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US5540935A (en) * | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
| JP3543347B2 (ja) * | 1994-01-24 | 2004-07-14 | 日本油脂株式会社 | 点火薬造粒物の製造方法 |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| CA2227989A1 (en) | 1995-08-01 | 1997-02-13 | Karen Ophelia Hamilton | Liposomal oligonucleotide compositions |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| US6218108B1 (en) * | 1997-05-16 | 2001-04-17 | Research Corporation Technologies, Inc. | Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor |
| US5865710A (en) * | 1996-08-01 | 1999-02-02 | Wilson-Hyde; Cynthia | Step aerobic platform |
| CA2283293A1 (en) * | 1997-03-11 | 1998-09-17 | Yale University | Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1 |
| AU731909B2 (en) * | 1997-07-01 | 2001-04-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US5976849A (en) * | 1998-02-05 | 1999-11-02 | Zeneca Limited | Human E3 ubiquitin protein ligase |
| CA2365625A1 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of substances to cells |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| BR0209646A (pt) | 2001-05-16 | 2006-10-10 | Novartis Ag | genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos |
| WO2003057847A2 (en) | 2001-12-31 | 2003-07-17 | Algos Therapeutics , Inc. | METHODS AND MATERIALS FOR MODULATING ENaC-BETA |
| DE60326961D1 (de) * | 2002-07-26 | 2009-05-14 | Novartis Vaccines & Diagnostic | Modifizierte kleine irns moleküle und methoden zu deren anwendung |
| JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
| GB0218970D0 (en) | 2002-08-14 | 2002-09-25 | Creative Peptides Sweden Ab | Fragments of Insulin c-peptide |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| AU2003293124A1 (en) | 2002-11-27 | 2004-06-23 | Artesian Therapeutics, Inc. | Heart failure gene determination and therapeutic screening |
| BRPI0215958B1 (pt) | 2002-11-29 | 2016-11-08 | Basf Ag | métodos para produção de metionina |
| DE10305213A1 (de) | 2003-02-07 | 2004-08-26 | Florian Prof. Dr.med. Lang | Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms |
| CA2520028A1 (en) * | 2003-03-31 | 2004-10-21 | University Of Iowa Research Foundation | Compounds and methods to enhance raav transduction |
| US7723509B2 (en) * | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| US20050256071A1 (en) * | 2003-07-15 | 2005-11-17 | California Institute Of Technology | Inhibitor nucleic acids |
| JP4530335B2 (ja) * | 2004-02-03 | 2010-08-25 | 独立行政法人科学技術振興機構 | 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬 |
| WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| SE0402832D0 (sv) * | 2004-11-18 | 2004-11-18 | Astrazeneca Ab | Methods |
| US20060166234A1 (en) * | 2004-11-22 | 2006-07-27 | Barbara Robertson | Apparatus and system having dry control gene silencing compositions |
| CA2590768A1 (en) * | 2004-12-14 | 2006-06-22 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of mll-af4 and uses thereof |
| CN101346393B (zh) * | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| US20070149456A1 (en) * | 2005-12-13 | 2007-06-28 | University Of Pittsburgh | Epithelial sodium channel inhibiting agents and uses therefor |
| JP5274461B2 (ja) | 2006-08-18 | 2013-08-28 | アローヘッド リサーチ コーポレイション | ポリヌクレオチドのインビボ送達のためのポリ結合体 |
| AU2007306542B2 (en) | 2006-10-11 | 2013-08-01 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Influenza targets |
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
-
2008
- 2008-06-12 AR ARP080102518A patent/AR066984A1/es not_active Application Discontinuation
- 2008-06-13 KR KR1020107000840A patent/KR101653008B1/ko active Active
- 2008-06-13 EP EP08761002A patent/EP2171059A2/en not_active Withdrawn
- 2008-06-13 TW TW097122240A patent/TWI444474B/zh not_active IP Right Cessation
- 2008-06-13 ES ES10163496T patent/ES2432643T3/es active Active
- 2008-06-13 EP EP10163499.6A patent/EP2223692B1/en active Active
- 2008-06-13 ES ES10163500T patent/ES2432644T3/es active Active
- 2008-06-13 EP EP10163500.1A patent/EP2223693B1/en active Active
- 2008-06-13 JP JP2010511658A patent/JP5485146B2/ja not_active Expired - Fee Related
- 2008-06-13 WO PCT/EP2008/057476 patent/WO2008152131A2/en not_active Ceased
- 2008-06-13 EA EA200901653A patent/EA200901653A1/ru unknown
- 2008-06-13 EP EP10163502.7A patent/EP2223695B1/en active Active
- 2008-06-13 AU AU2008263876A patent/AU2008263876B2/en not_active Ceased
- 2008-06-13 SG SG201101084-0A patent/SG169988A1/en unknown
- 2008-06-13 ES ES10163499T patent/ES2432157T3/es active Active
- 2008-06-13 CA CA2690674A patent/CA2690674C/en active Active
- 2008-06-13 KR KR1020167023121A patent/KR101821081B1/ko not_active Expired - Fee Related
- 2008-06-13 MX MX2009013609A patent/MX2009013609A/es active IP Right Grant
- 2008-06-13 SG SG10201601846VA patent/SG10201601846VA/en unknown
- 2008-06-13 ES ES10163498.8T patent/ES2439277T3/es active Active
- 2008-06-13 CL CL2008001756A patent/CL2008001756A1/es unknown
- 2008-06-13 ES ES10163502T patent/ES2432532T3/es active Active
- 2008-06-13 SG SG10201404955RA patent/SG10201404955RA/en unknown
- 2008-06-13 ES ES10163501T patent/ES2432158T3/es active Active
- 2008-06-13 EP EP10163496.2A patent/EP2224004B1/en active Active
- 2008-06-13 BR BRPI0813680A patent/BRPI0813680A8/pt not_active IP Right Cessation
- 2008-06-13 TW TW103118914A patent/TWI552753B/zh not_active IP Right Cessation
- 2008-06-13 CN CN2008801032623A patent/CN101778941B/zh active Active
- 2008-06-13 PE PE2008001013A patent/PE20090942A1/es not_active Application Discontinuation
- 2008-06-13 EP EP10163498.8A patent/EP2224005B1/en active Active
- 2008-06-13 EP EP10163501.9A patent/EP2223694B1/en active Active
- 2008-06-13 TW TW105120348A patent/TWI629063B/zh not_active IP Right Cessation
- 2008-06-16 US US12/140,112 patent/US7718632B2/en active Active
-
2009
- 2009-11-26 IL IL202366A patent/IL202366A0/en unknown
- 2009-12-02 CR CR11136A patent/CR11136A/es not_active Application Discontinuation
- 2009-12-11 GT GT200900315A patent/GT200900315A/es unknown
- 2009-12-11 EC EC2009009794A patent/ECSP099794A/es unknown
- 2009-12-11 TN TNP2009000521A patent/TN2009000521A1/fr unknown
- 2009-12-11 CO CO09142201A patent/CO6251331A2/es not_active Application Discontinuation
- 2009-12-14 SV SV2009003434A patent/SV2009003434A/es unknown
- 2009-12-15 CU CU20090215A patent/CU23774A3/es not_active IP Right Cessation
-
2010
- 2010-01-06 US US12/683,146 patent/US9074212B2/en active Active
- 2010-01-07 MA MA32484A patent/MA31564B1/fr unknown
- 2010-04-30 US US12/771,518 patent/US7939508B2/en active Active
- 2010-04-30 US US12/771,614 patent/US8168606B2/en not_active Expired - Fee Related
- 2010-04-30 US US12/771,470 patent/US7943592B2/en active Active
- 2010-04-30 US US12/771,566 patent/US8119612B2/en active Active
-
2014
- 2014-02-19 JP JP2014029519A patent/JP5719047B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-19 JP JP2015055783A patent/JP6193906B2/ja not_active Expired - Fee Related
- 2015-06-03 US US14/729,104 patent/US9476052B2/en active Active
-
2016
- 2016-09-09 US US15/260,824 patent/US9914927B2/en active Active
-
2017
- 2017-08-01 JP JP2017149211A patent/JP6680728B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-18 US US15/874,396 patent/US10544418B2/en active Active
-
2020
- 2020-01-24 US US16/752,325 patent/US11208662B2/en active Active
- 2020-03-17 JP JP2020046007A patent/JP7157775B2/ja active Active
-
2021
- 2021-12-23 US US17/560,475 patent/US20220112505A1/en not_active Abandoned
-
2022
- 2022-04-05 US US17/713,763 patent/US20220235361A1/en not_active Abandoned
- 2022-10-07 JP JP2022162309A patent/JP2022188234A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020094063A5 (enExample) | ||
| JP2022188234A5 (enExample) | ||
| US7998940B2 (en) | Aptamers to von Willebrand factor and their use as thrombotic disease therapeutics | |
| US7589073B2 (en) | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics | |
| CN109414448B (zh) | 用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子 | |
| JP5773535B2 (ja) | インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物 | |
| US7566701B2 (en) | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics | |
| AU2017326372B2 (en) | Modified oligonucleotides and methods of use | |
| AU2011244335B2 (en) | Organic compositions to treat Beta-ENaC-related diseases | |
| CN111511914B (zh) | 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染 | |
| JP2008526876A5 (enExample) | ||
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| KR20160002862A (ko) | Mir-122를 조정하기 위한 마이크로rna 화합물 및 방법 | |
| JP2009502138A5 (enExample) | ||
| RU2008121953A (ru) | Ирнк-ингибирование репликации вируса гриппа | |
| WO2022125789A1 (en) | Compositions and methods for treating, ameliorating, and/or preventing viral infections | |
| RU2822093C1 (ru) | Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке | |
| KR20250116748A (ko) | 유전자 침묵 기술로서 산재된 데옥시리보뉴클레오타이드를 갖는 비대칭 짧은 이중체 rna 및 이의 용도 | |
| AU2015221515B2 (en) | Organic compositions to treat Beta-ENaC-related diseases | |
| HK40078455A (en) | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv | |
| HK40004694A (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection |